Lupkynis
(Voclosporin)ApprovedSmall molecule
Aurinia PharmaceuticalsVoclosporin is used to treat lupus nephritis, which is kidney damage caused by lupus (an autoimmune disease). It helps reduce inflammation in the kidneys and can improve kidney function in patients with this condition.[2] Lupkynis is currently approved and in use across 14 indications[4].[1]
Lupkynis is one of 295 small molecule programs targeting Panuveitis. It is currently in Approved.
14
Indications
21
Total Trials
2
Active Trials
294
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
605 competitors in Psoriasis
#DrugCompanyPhaseTrials
1Lupkynis
Aurinia PharmaceuticalsApproved
Cosentyx
NovartisPreclinical
Stelara
Johnson & JohnsonPreclinical
Taltz
Eli LillyPreclinical
Bimzelx
UCBPreclinical
Humira
CCelltrion
Preclinical
Ilumya
Sun Pharmaceutical Industries, Inc.Preclinical
Raptiva
RochePreclinical
Remicade
OOrganon and Co
Preclinical
Siliq
BBausch Health Americas, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lupus3 trials
Lupus Nephritis2 trials
Safety and Efficacy2 trials
Psoriasis2 trials
8 more indications
Treatment1 trial
Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05306873·12 enrolled
Interaction1 trial
Focal Segmental Glomerulosclerosis1 trial
Eye Disease1 trial
Keratoconjunctivitis sicca1 trial
Regulatory
FDA Approval Timeline[5]
Jan 22, 2021
LUPKYNIS
NDA NDA213716
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lupkynis drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Voclosporin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
- [8]